- Home
- DLHC vs HRMY Comparison
DLHC vs HRMY Comparison
Compare DLHC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- HRMY
- Stock Information
- Founded
- DLHC 1969
- HRMY 2017
- Country
- DLHC United States
- HRMY United States
- Employees
- DLHC N/A
- HRMY N/A
- Industry
- DLHC Business Services
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- HRMY Health Care
- Exchange
- DLHC Nasdaq
- HRMY Nasdaq
- Market Cap
- DLHC N/A
- HRMY 1.6B
- IPO Year
- DLHC N/A
- HRMY 2020
- Fundamental
- Price
- DLHC $4.15
- HRMY $34.05
- Analyst Decision
- DLHC
- HRMY Strong Buy
- Analyst Count
- DLHC 0
- HRMY 8
- Target Price
- DLHC N/A
- HRMY $52.88
- AVG Volume (30 Days)
- DLHC 95.0K
- HRMY 701.6K
- Earning Date
- DLHC 05-07-2025
- HRMY 05-06-2025
- Dividend Yield
- DLHC N/A
- HRMY N/A
- EPS Growth
- DLHC 75.08
- HRMY 13.13
- EPS
- DLHC 0.38
- HRMY 2.62
- Revenue
- DLHC $377,074,000.00
- HRMY $744,852,000.00
- Revenue This Year
- DLHC N/A
- HRMY $20.06
- Revenue Next Year
- DLHC N/A
- HRMY $18.40
- P/E Ratio
- DLHC $10.71
- HRMY $13.10
- Revenue Growth
- DLHC N/A
- HRMY 20.62
- 52 Week Low
- DLHC $2.72
- HRMY $26.47
- 52 Week High
- DLHC $12.23
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- DLHC 59.16
- HRMY 69.53
- Support Level
- DLHC $3.41
- HRMY $29.82
- Resistance Level
- DLHC $4.05
- HRMY $30.61
- Average True Range (ATR)
- DLHC 0.20
- HRMY 1.12
- MACD
- DLHC 0.11
- HRMY 0.74
- Stochastic Oscillator
- DLHC 89.16
- HRMY 92.78
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.